| Filed On | Filing |
|---|---|
| 26 Oct 2026 | S-1 |
| 20 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 19, 2026, is entered into by and among First Tracks Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (ind... |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SECURITIES PURCHASE AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 19... |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms |
| 17 Sep 2026 |
Form 4: Orwin John A, Director
Received 1,300 shares by exercise or conversion |
| 04 Sep 2026 |
Form 4: Ware J. Anthony, Director
Received 39,265 shares by exercise or conversion ($225K) · Sold 39,265 shares ($1.76M) |
| 02 Sep 2026 | 144 |
| 18 Aug 2026 |
Form 4: Stone Benjamin, Chief Business Officer
Granted 60,492 Performance Stock Units |
| 18 Aug 2026 |
Form 4: Lizzul Paul F., Chief Medical Officer
Granted 60,492 Performance Stock Units |
| 18 Aug 2026 |
Form 4: Faga Daniel, Director
Granted 193,575 Performance Stock Units |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | 424B3 |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 | Form 3/A: Lizzul Paul F., Chief Medical Officer |
| 07 Aug 2026 | Form 3/A: Stone Benjamin, Chief Business Officer |
| 07 Aug 2026 | Form 3/A: Faga Daniel, Director |
| 06 Aug 2026 | SCHEDULE 13G |
Loading...
